BioLineRx is a pre-commercial-stage biopharmaceutical company pursuing life-changing therapies for people living with certain cancers and rare disease. Headquartered in Israel, with operations in the U.S., BioLineRx is driving innovative therapeutics with end-to-end expertise in drug development and commercialization, ensuring life-changing discoveries move beyond the bench to the bedside.

The company is advancing a pipeline of investigational medicines for patients with multiple myeloma, sickle cell disease, pancreatic cancer, and other solid tumors.

Corporate Presentation

File PRESENTATION

BioLineRx Corporate Presentation
Shape Shape

Press Releases

BioLineRx Announces Encouraging Data from Pilot Phase of Phase 2 Combination Clinical Trial with Motixafortide in First-Line Pancreatic Cancer (PDAC)

 Press Release / 28 Sep 2023

BioLineRx Announces Acceptance of Oral Presentation on Pilot Phase Data from Phase 2 Combination Clinical Trial with Motixafortide in First-Line PDAC at AACR Special Conference on Pancreatic Cancer

 Press Release / 19 Sep 2023

BioLineRx Announces FDA Approval of APHEXDA™ (motixafortide) in Combination with Filgrastim (G-CSF) to Mobilize Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Patients with Multiple Myeloma

 Press Release / 11 Sep 2023
View All Press Releases

Upcoming Events

APHEXDA Investor Conference Call
Event / Sep 12, 2023 8:00 AM EDT
View All Events

IR Contact

John Lacey, MS, MBA Head of Investor Relations & Corporate Communications
IR@BioLineRx.com

Shape
Shape
Potential life-changing treatments are on the way

Each molecule in our development pipeline is carefully selected for its potential ability to improve upon the standard of care, delivering maximum value to patients

Discover our Pipeline